Business Wire

Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant

Share

Celltrion Group announced today results for its cocktail therapy candidates including neutralisation data against the Omicron variant (B.1.1.529).

The Phase I clinical trial is a randomised, double- blind and placebo- controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of CT-P63 in 24 healthy subjects in Poland.1 The study met its primary objectives with data showing CT-P63 to be safe and well tolerated, with no significant drug- related adverse events (AEs).

In an experiment conducted in partnership with the National Institutes of Health (NIH), CT-P63 showed strong neutralising activity against the Omicron variant based on structural analysis by X- ray crystallography and neutralisation data from pseudo- virus testing. Celltrion anticipates results of the SARS-CoV-2 Omicron variant assays and animal model studies by the end of the first quarter this year.

In order to elicit potent neutralising antibody response against the new emerging variants, Celltrion previously identified a total of 38 potent neutralising antibodies against SARS-CoV-2 in which antibody candidate No. 32 (CT-P63) produced high neutralisation titres against new emerging strains. CT-P63 has previously been demonstrated to have neutralising activity against the most common variants, including the Alpha, Beta, Gamma and Delta variants.

“The positive results demonstrate the potential of our cocktail therapy to retain neutralising ability against the Omicron variant” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. “We are confident that our antibody platform including Regkirona and CT-P63 will provide significant benefit for patients with COVID-19. Regkirona is given to a patient intravenously, so the drug could effectively treat patients hospitalised with COVID-19 at an early stage, while the nebulised cocktail therapy could address patients’ unmet needs for at- home treatment. We plan to discuss large- scale clinical trial for our nebulised cocktail therapy (CT-P63 in combination with Regkirona™) with regulatory agencies worldwide in the near future.”

- ENDS -

Notes to Editors:

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us.

About regdanvimab (CT-P59)

CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus. In vitro and in vivo pre- clinical studies showed that CT-P59 strongly binds to SARS-CoV-2 RBD and significantly neutralises the wild type and mutant variants of concern. In in vivo models, CT-P59 effectively reduced the viral load of SARS-CoV-2 and inflammation in lung. Results from the global phase I and phase II/III clinical trials of CT-P59 demonstrated a promising safety, tolerability, antiviral effect and efficacy profile in patients with mild-to-moderate symptoms of COVID-19.2 The EC granted marketing authorisation for Celltrion’s regdanvimab following positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in November 2021.

About CT-P63

CT-P63 is a monoclonal antibody targeting SARS-CoV-2 spike receptor binding domain (RBD) as a treatment for COVID-19 infection. CT-P63 is currently being developed as a potential treatment for SARS-CoV-2 infection.

About nebulised formulation

The nebulised formulation of the monoclonal antibody not only targets SARS-CoV-2 spike receptor binding domain (RBD) and elicit neutralising antibody response but it also has ‘trapping’ mechanism of action and thereby neutralises and traps in mucus with exceptional potency. The muco-trapping antibody platform directly traps the virus in airway mucus, preventing the local spread of the infection, and quickly eliminating the virus from the lungs through the body's natural ability to clear mucus. Nebulized formulation can be readily self-administered by patients, extend critical drug supplies to more patients by reducing the dosage needed, and does not place excessive demands on healthcare staff and infusion clinic space that intravenous (IV) drugs do.

FORWARD LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References

____________________________

1 ClinicalTrials.gov. To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects. Available at: https://clinicaltrials.gov/ct2/show/NCT05017168#wrapper [Last Accessed January 2022]
2 Celltrion Data on file

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Barber
hbarber@hanovercomms.com  
+44 (0) 07759 301620 

Donna Curran
dcurran@hanovercomms.com
+44 (0) 7984 550312

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Square Announces Official Launch in Spain After Successful Early Access Programme25.1.2022 13:30:00 EET | Press release

Square, the company specialising in software, payments, and hardware solutions for businesses of all sizes, announces its arrival in Spain following a successful Early Access Programme. Starting today, Spanish entrepreneurs, freelancers and business owners will be able to use Square's ecosystem of tools; the only end-to-end solution of its kind in the country. "We’ve been trialing Square’s suite of products both in-store and online and we love it,” said Miguel Gil, owner of Hop Hop Hurrah , one of the first businesses to use Square’s products in Spain. “Having a point-of-sale system with integrated payments and omnichannel solutions has transformed the way we’re able to run our business, making it an easy and seamless process. We’re pleased we were able to switch to Square and feel much more confident in our ability to grow, ensuring we never miss a sale, as we look towards the future.” Square is part of Block, Inc. a global technology company focused on financial services, founded in

J.P. Morgan to Acquire a Stake in Viva Wallet25.1.2022 13:00:00 EET | Press release

J.P. Morgan (NYSE: JPM) announced today that it has entered into an agreement with Viva Wallet Holdings Software Development S.A. (Viva Wallet), a leading European cloud-based payments fintech company, and its existing shareholders to acquire an ownership stake of approximately 49 percent, subject to regulatory approvals. Financial terms of the transaction were not disclosed. “We are very excited to make a strategic investment in Viva Wallet to support their vision to empower new growth and payments innovation targeted at European small and midsize businesses (SMBs) and middle market merchant services clients,” said Takis Georgakopoulos, Global Head of J.P. Morgan Payments. “The European payments landscape is fragmented yet large in terms of opportunity, with more than 17 million merchants1 ready to implement scalable payments solutions and this is a big focus area for added growth for J.P. Morgan Payments in the future.” Founded in 2000, Viva Wallet is headquartered in Athens, Greece,

The O-RAN ALLIANCE Announces the 5th Release of Its Open Source Software and An Industry Briefing at MWC Barcelona25.1.2022 12:49:00 EET | Press release

O-RAN ALLIANCE: O-RAN ALLIANCE Industry Briefing, March 1, 2022 at MWC Barcelona O-RAN ALLIANCE plans to hold its next industry event on March 1, 2022 from 17:15-18:00 CET, hosted at the Deutsche Telekom booth at MWC Barcelona 2022, Hall 3 Stand 3M31. The event will include keynotes from O-RAN ALLIANCE’s leadership and an industry panel discussion. Save the date and follow our website for further updates. 5th Release of Open Software for the RAN – “E” – Delivered by the O-RAN Software Community The O-RAN Software Community (OSC or O-RAN SC) was formed in partnership with the Linux Foundation in April 2019, to support software development of open RAN solutions available to everyone. In December 2021, following on the half year release cycle, the OSC published its 5th open software release dubbed "E". The E release further enhances the traffic steering use case, introduces basic RAN slicing feature and closed loop slice SLA assurance. With these enhanced features and the end-to-end integ

Samsung Introduces Smart All-in-One Fingerprint Security IC for Biometric Payment Cards25.1.2022 12:00:00 EET | Press release

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced its new fingerprint security IC (integrated circuit) ─ S3B512C ─ with enhanced security features. The new solution is EMVCo and Common Criteria Evaluation Assurance Level (CC EAL) 6+ certified and performs in line with Mastercard’s latest Biometric Evaluation Plan Summary (BEPS) specifications for biometric payment cards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005609/en/ Samsung-Smart-All-in-One-Fingerprint-Security-IC (Photo: Business Wire) “S3B512C combines a fingerprint sensor, Secure Element (SE) and Secure Processor, adding an extra layer of authentication and security in payment cards,” said Kenny Han, vice president of System LSI marketing at Samsung Electronics. “The S3B512C is primarily designed for payment cards but can also be used in cards that require highly secured authentications such as student o

EcoVadis Upgrades INNIO Jenbacher Rating to Gold Medal for Continued Commitment to Global Sustainability25.1.2022 12:00:00 EET | Press release

INNIO today announced that its Jenbacher business unit has been recognized by EcoVadis with a Gold Medal as part of its annual sustainability performance rating, placing INNIO Jenbacher in the top 1% of industry peers evaluated by EcoVadis. EcoVadis awarded INNIO Jenbacher the upgrade from a Silver to a Gold Medal rating for its demonstrated improvements and contributions towards sustainable growth in the past year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005260/en/ INNIO Jenbacher, Recipient of EcoVadis Gold Medal Rating (Photo: Business Wire) Performed annually, EcoVadis’ assessment focuses on 21 issues grouped into four key themes: Environment, Labor & Human Rights, Ethics and Sustainable Procurement. These criteria are based upon international sustainability standards, including the Global Compact Principles, the International Labour Organization conventions and the Global Reporting Initiative standard. “As

Reply Takes the Top Spot in PAC RADAR as a Leading SAP Service Provider25.1.2022 11:30:00 EET | Press release

Reply is among the most competent and leading SAP service providers in the PAC RADAR "Leading Providers of SAP Services in Germany 2022", an industry study by the independent research and consulting company Teknowlogy Group. The study analyses the service performance of 20 international consulting firms and service providers that implement SAP projects in dedicated IT market segments. PAC RADAR compares the strategy and development of the providers and evaluates them according to market strength and competence. These include project experience, the offered service spectrum and local delivery capability. When comparing the vendors in the ranking, Reply is rated as "Best in Class" vendor in the market for SAP Customer Experience (CX) related services. After winning the SAP Customer Experience Award for Partner Innovation 2021 and being among the finalists of the SAP Pinnacle Awards 2021, this exceptionally good performance confirms the success of the partnership with SAP. Reply achieved

Temenos Announces Infinity Digital for Salesforce to Combine Enhanced Customer Engagement With Industry Leading Banking Platform25.1.2022 10:30:00 EET | Press release

Temenos (SIX: TEMN), the banking software company, today announced the availability of Infinity Digital for Salesforce that brings together the worlds of CRM, assisted channels and digital channels onto a single platform, available here on Salesforce AppExchange – the world’s leading enterprise cloud marketplace. This solution integrates Salesforce Financial Services Cloud with Temenos’ digital banking platform, giving customer-facing teams in banks a holistic view of their customers surfacing both customer engagement and transactional banking data across all channels and transactional systems. Infinity Digital for Salesforce offers banks synchronization between Salesforce Financial Services Cloud and the bank’s core banking systems. It helps banks achieve higher efficiency and streamlining of servicing, onboarding and origination processes with better personalization and greater customer experience. The banking industry has fundamentally changed in recent years; business models are dr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom